RBC Capital Maintains Outperform on Moderna, Lowers Price Target to $190
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Moderna (NASDAQ:MRNA) but lowered the price target from $200 to $190.

August 04, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Moderna's price target has been lowered from $200 to $190 by RBC Capital, though the 'Outperform' rating is maintained.
The news is directly about Moderna and is likely to influence investor sentiment. While the 'Outperform' rating is maintained, which is positive, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100